Technical Advantages
- Patent granted for umbilical cord mesenchymal stem cell-derived exosome culture technology
- Product has undergone clinical trials and results will be published in an international journal
- Exosome concentration reaching up to 200 billion particles/mL
- Fully automated GTP-compliant manufacturing process to ensure quality and production output
- The production equipment has obtained TFDA Class II Innovative Medical Device certification, leading the industry in Taiwan.
Market Deployment Strategy
- Phased market expansion: Initial focus on the Taiwanese market, followed by expansion into the Asia-Pacific region, partnership with Japan’s largest exosome company, and eventual entry into North American and European markets.
- Global deployment plan: Establish subsidiaries in the United States, Europe and Asia, collaborating with leading medical research teams to advance technological development.
- Brand and influence: We are committed to becoming a global leader in regenerative medicine, enhancing product competitiveness and international market influence.
